As of 2025-10-17, the Relative Valuation of Aclaris Therapeutics Inc (ACRS) is (23.80) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.05 USD, the upside of Aclaris Therapeutics Inc based on Relative Valuation is -1261.1%.
The range of the Relative Valuation is (21.90) - (25.56) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.6x - 20.6x | 19.0x |
| Forward P/E multiples | 17.6x - 22.1x | 19.4x |
| Fair Price | (21.90) - (25.56) | (23.80) |
| Upside | -1168.4% - -1346.6% | -1261.1% |
| Date | P/E |
| 2025-10-16 | -1.65 |
| 2025-10-15 | -1.55 |
| 2025-10-14 | -1.46 |
| 2025-10-13 | -1.54 |
| 2025-10-10 | -1.50 |
| 2025-10-09 | -1.57 |
| 2025-10-08 | -1.53 |
| 2025-10-07 | -1.48 |
| 2025-10-06 | -1.53 |
| 2025-10-03 | -1.50 |
| 2025-10-02 | -1.48 |
| 2025-10-01 | -1.50 |
| 2025-09-30 | -1.53 |
| 2025-09-29 | -1.54 |
| 2025-09-26 | -1.60 |
| 2025-09-25 | -1.50 |
| 2025-09-24 | -1.50 |
| 2025-09-23 | -1.47 |
| 2025-09-22 | -1.55 |
| 2025-09-19 | -1.54 |
| 2025-09-18 | -1.57 |
| 2025-09-17 | -1.46 |
| 2025-09-16 | -1.48 |
| 2025-09-15 | -1.48 |
| 2025-09-12 | -1.57 |
| 2025-09-11 | -1.58 |
| 2025-09-10 | -1.64 |
| 2025-09-09 | -1.71 |
| 2025-09-08 | -1.67 |
| 2025-09-05 | -1.69 |
| 2025-09-04 | -1.67 |
| 2025-09-03 | -1.66 |
| 2025-09-02 | -1.60 |
| 2025-08-29 | -1.55 |
| 2025-08-28 | -1.48 |
| 2025-08-27 | -1.46 |
| 2025-08-26 | -1.46 |
| 2025-08-25 | -1.45 |
| 2025-08-22 | -1.45 |
| 2025-08-21 | -1.41 |
| 2025-08-20 | -1.46 |
| 2025-08-19 | -1.44 |
| 2025-08-18 | -1.49 |
| 2025-08-15 | -1.50 |
| 2025-08-14 | -1.36 |
| 2025-08-13 | -1.37 |
| 2025-08-12 | -1.32 |
| 2025-08-11 | -1.32 |
| 2025-08-08 | -1.31 |
| 2025-08-07 | -1.26 |